博瑞生物医药（苏州）股份有限公司自愿披露关于公司部分产品拟中选国家药品接续采购的公告

Core Viewpoint - The company, Bory Pharmaceutical (Suzhou) Co., Ltd., has announced that its subsidiary, Bory Pharmaceutical, is expected to be selected for the national drug procurement program, which could significantly impact its sales and market presence [1][2]. Group 1: Product Selection Details - The company participated in the national drug procurement program for products whose agreements have expired, with the selection results published on February 10, 2026 [1]. - Four products from the company are expected to be selected, which accounted for a total sales revenue of 88.8475 million yuan in the first three quarters of 2025, representing 10.16% of the company's total revenue during that period [2]. Group 2: Impact of Selection - The procurement cycle for the selected products will last until December 31, 2028, with medical institutions prioritizing the use of these selected drugs, which is expected to enhance sales volume and market share [2]. - If contracts are signed and implemented, it will further boost the company's brand image and sales performance [2].